CL
CLYYF.US Celyad Oncology SA
- Market cap
- USD 21.0M
- P/E
- 3.1x
- P/B
- 14.92x
- ROE
- -382.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CLYYF.US undervalued?
Graham numberCLYYF.US trades 43.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Celyad Oncology SA fundamental analysis
No fundamental analysis for Celyad Oncology SA yet.
Celyad Oncology SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Full company profileCelyad Oncology SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Celyad Oncology SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 10.0M | 3.54M | 3.12M | 6.00K | 5.00K | 0.00 | 0.00 | 102K | 186K | 21.0K | - |
| Gross Profit | 8.47M | 3.03M | 3.12M | 6.00K | 5.00K | -1.52M | -1.44M | 33.0K | 174K | 1.93M | -171K |
| Operating Income | -25.6M | -52.9M | -38.2M | -28.9M | -17.0M | -26.4M | -40.9M | -8.46M | -5.86M | -7.18M | -5.27M |
| EBITDA | -22.0M | -54.4M | -36.3M | -26.5M | -14.9M | -25.4M | -39.7M | -7.76M | -5.42M | -7.01M | -5.10M |
| Net Income | -23.6M | -56.4M | -37.4M | -28.6M | -17.5M | -26.5M | -40.9M | -8.45M | -5.82M | 830K | -4.80M |
| EPS | -2.53 | -5.86 | -3.36 | -2.29 | -1.26 | -1.70 | -1.81 | -0.33 | -0.14 | 0.02 | -0.11 |
| Balance Sheet | |||||||||||
| Total Assets | 139M | 77.6M | 94.3M | 89.8M | 66.1M | 79.9M | 19.7M | 16.3M | 9.93M | 4.30M | 2.32M |
| Total Liabilities | 47.9M | 30.1M | 38.7M | 44.2M | 35.1M | 36.3M | 15.4M | 9.98M | 26.0M | 1.86M | 1.07M |
| Shareholders' Equity | 90.9M | 47.5M | 55.6M | 45.6M | 31.0M | 43.6M | 4.32M | 6.30M | -16.1M | 2.44M | 1.25M |
| Cash & Short-term Investments | 82.6M | 33.9M | 49.7M | 39.3M | 17.2M | 30.0M | 12.4M | 7.00M | 4.20M | 1.71M | 121K |
| Total Debt | 1.48M | 1.44M | 1.65M | 4.36M | 3.64M | 2.63M | 255K | 1.06M | 17.5M | - | 25.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -24.7M | -49.5M | -27.2M | -28.2M | -27.7M | -26.6M | -28.0M | -15.2M | -5.68M | -6.90M | - |
| Capital Expenditure | 1.78M | 858K | 1.77M | 622K | 319K | 393K | 123K | 899K | 118K | 0.00 | - |
| Free Cash Flow | -26.5M | -50.4M | -29.0M | -28.8M | -28.0M | -27.0M | -28.1M | -16.1M | -5.68M | -6.90M | - |
| Ratios | |||||||||||
| ROE | -26.0% | -118.6% | -67.3% | -62.8% | -56.5% | -60.8% | -948.2% | -134.0% | - | 34.1% | -382.9% |
| ROA | -17.0% | -72.6% | -39.7% | -31.9% | -26.5% | -33.2% | -207.6% | -51.9% | -58.7% | 19.3% | -206.9% |
| Net Profit Margin | -235.8% | -1,593.1% | -1,201.5% | -477,200.0% | -350,020.0% | - | - | -8,282.4% | -3,131.2% | 3,952.6% | - |
| Debt to Equity | 0.02x | 0.03x | 0.03x | 0.10x | 0.12x | 0.06x | 0.06x | 0.17x | - | - | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Celyad Oncology SA dividends
Celyad Oncology SA has not paid dividends in the last 10 fiscal years.
Who owns Celyad Oncology SA
- Insiders 10.28%
- Institutions 55.49%
- Public & others 34.23%
- Shares outstanding 74.9M
- Free float 14.2M
Celyad Oncology SA company profile
- Company name
- Celyad Oncology SA
- Ticker
- CLYYF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
- Phone
- 32 1 039 41 00
- Website
- celyad.com
About Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Celyad Oncology SA management
6- Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BMECo-Founder & Non-Executive Director · born 1956
- Mr. Hannes IserentantGeneral Manager · born 1978
- Mr. David GeorgesVice President of Finance & Administration · born 1976
- Sara ZelkovicCommunications & Investor Relations Director
- Ms. An PhanHead of Legal · born 1975
- Mr. Philippe DechampsCorporate Secretary · born 1970